ASML CFO: US MATCH Act Restricting DUV Exports to China Would Backfire
nashnova research
ASML CFO Roger Dassen called the proposed MATCH Act a "bad idea," warning that blocking DUV lithography sales to China would accelerate China's domestic chip R&D rather than contain it — while directly hitting ASML's revenue.
What did ASML's executive actually say?
CFO Roger Dassen stated on the Q3 earnings media call that the MATCH Act is a "bad idea."
His core argument: restricting DUV exports will not stop China's progress — it will accelerate China's self-reliance in competitive technologies, the exact opposite of the legislation's intent.
Dassen added a note of optimism, saying he believes "common sense will ultimately prevail" — suggesting the bill is far from certain to pass.
What would the MATCH Act actually restrict?
The current export-control landscape: advanced EUV lithography tools — which etch the finest chip circuits using extreme-ultraviolet light — are already banned from sale to China. But older DUV tools — deep-ultraviolet lithography, using longer-wavelength light to pattern chips at lower precision — are still permitted.
The MATCH Act aims to extend the ban from EUV to DUV, further tightening chip-equipment exports to China.
This means → if the bill passes, ASML would lose its last major lawful revenue stream in the Chinese market.
Why does Dassen call it "counterproductive"?
In plain terms = the logic is straightforward — cut off supply, and the buyer is forced to build its own. The tighter the restriction, the stronger the incentive to invest in domestic alternatives.
This reflects a pattern already visible: after the EUV ban, China's investment in domestic semiconductor supply-chain substitution measurably accelerated. Dassen's concern is grounded in precedent.
For investors, the debate boils down to a single trade-off: keep exporting and protect ASML's China revenue, or impose a full blockade and risk creating a Chinese competitor that no longer needs ASML at all.
How likely is the bill to pass?
Dassen flagged the window as after the US midterm elections, meaning the bill is still in the congressional review stage and has not been enacted.
His optimism about "common sense" signals that ASML sees political room for the bill to stall — it is not a foregone conclusion.
But uncertainty itself is the risk — as long as the bill remains unresolved, the market will keep repricing ASML's China business outlook.
市场有风险，内容仅供研究参考，不构成投资建议。